Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company's lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:ABEO
- CUSIP: N/A
- Web: www.abeonatherapeutics.com
- Market Cap: $328.34 million
- Outstanding Shares: 40,255,000
- 50 Day Moving Avg: $8.34
- 200 Day Moving Avg: $6.07
- 52 Week Range: $3.90 - $10.26
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -12.19
- P/E Growth: 0.00
- Annual Revenue: $842,999.00
- Price / Sales: 372.47
- Book Value: $2.21 per share
- Price / Book: 3.53
- EBIDTA: ($23,800,000.00)
- Net Margins: -2,746.38%
- Return on Equity: -26.66%
- Return on Assets: -23.94%
- Current Ratio: 14.08%
- Quick Ratio: 10.53%
- Average Volume: 496,286 shs.
- Beta: 2.33
- Short Ratio: 11.42
Frequently Asked Questions for Abeona Therapeutics (NASDAQ:ABEO)
What is Abeona Therapeutics' stock symbol?
Abeona Therapeutics trades on the NASDAQ under the ticker symbol "ABEO."
How were Abeona Therapeutics' earnings last quarter?
Abeona Therapeutics Inc. (NASDAQ:ABEO) issued its quarterly earnings data on Tuesday, August, 15th. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $0.07. The firm had revenue of $0.22 million for the quarter, compared to analyst estimates of $0.21 million. Abeona Therapeutics had a negative return on equity of 26.66% and a negative net margin of 2,746.38%. View Abeona Therapeutics' Earnings History.
When will Abeona Therapeutics make its next earnings announcement?
Where is Abeona Therapeutics' stock going? Where will Abeona Therapeutics' stock price be in 2017?
6 brokerages have issued 12-month price objectives for Abeona Therapeutics' shares. Their predictions range from $15.00 to $22.00. On average, they expect Abeona Therapeutics' share price to reach $19.17 in the next year. View Analyst Ratings for Abeona Therapeutics.
What are analysts saying about Abeona Therapeutics stock?
Here are some recent quotes from research analysts about Abeona Therapeutics stock:
- 1. According to Zacks Investment Research, "Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States. " (8/16/2017)
- 2. Maxim Group analysts commented, "Abeona announced that the company has received guidance from the FDA for accelerating EB-101 (gene therapy corrected skin grafts) into a P3 pivotal program in epidermolysis bullosa (EB). EB-101 has demonstrated proof of concept (POC) data in the first 6 patients of the P1/2 study (Recessive Dystrophic Epidermolysis Bullosa, or RDEB), demonstrating durable wound closure, in some cases for over 3 years (standard skin graft would fall off within a few months). Pending protocol approval, the pivotal program is expected to initiate in early 2018." (7/18/2017)
- 3. Cantor Fitzgerald analysts commented, "At the ASGCT meeting in Washington D.C., Abeona announced initial 30-day data in two patients treated with a high dose of ABO-102." (5/12/2017)
- 4. FBR & Co analysts commented, "On March 31, Abeona Therapeutics reported results for a year in which all clinical programs achieved important regulatory and clinical milestones. Most notably, 2016 culminated in the initiation of dosing in the high-dose cohort of Abeona’s Phase I/II trial with ABO-102 in children with Sanfilippo Syndrome Type A (MPS IIIA). We think this milestone is significant as it highlights ABO-102’s continued safety, its promising biopotency, as well as its designation for FDA Fast Track status for a rare pediatric disease, as well as for an orphan disease. It also supports our view that Abeona’s ability to rapidly advance therapies with high-value potential and short pathways to regulatory approval remains under-appreciated. We look next for a clinical update on the EB-101 Phase I study later this month, an update on the Phase I/II study with ABO-101 in MPS IIIB, as well as Abeona’s three other ongoing rare disease programs in the next three to six months to be positive catalysts for ABEO stock." (4/5/2017)
Who are some of Abeona Therapeutics' key competitors?
Some companies that are related to Abeona Therapeutics include Mesoblast Limited (MESO), Intellia Therapeutics (NTLA), ImmunoGen (IMGN), ANI Pharmaceuticals (ANIP), KALA PHARMCTLS (KALA), Inovio Pharmaceuticals (INO), WAVE Life Sciences (WVE), Cara Therapeutics (CARA), PDL BioPharma (PDLI), AC Immune SA (ACIU), Celyad SA (CYAD), Agenus (AGEN), Concert Pharmaceuticals (CNCE), Adamas Pharmaceuticals (ADMS), Puretech Health PLC (PRTC), Celldex Therapeutics (CLDX), Novavax (NVAX) and Corvus Pharmaceuticals (CRVS).
Who are Abeona Therapeutics' key executives?
Abeona Therapeutics' management team includes the folowing people:
- Steven H. Rouhandeh, Executive Chairman of the Board
- Timothy J. Miller Ph.D., President, Chief Executive Officer, Director
- Jeffrey B. Davis, Chief Operating Officer
- David P. Nowotnik Ph.D., Senior Vice President - Research and Development
- Harrison G. Wehner III, Senior Vice President - Plasma
- Stephen B. Thompson, Chief Accounting Officer, Vice President - Finance, Treasurer, Secretary
- Michelle Berg, Vice President - Communications & Operations
- Andre'a Lucca, Vice President - Communications & Operations
- Phil Maples Ph.D., Vice President - Therapeutics Development and Quality Management
- Kaye Spratt Ph.D., Vice President - Regulatory & Quality Assurance
Who owns Abeona Therapeutics stock?
Abeona Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (2.69%), Nexthera Capital LP (0.88%), Royce & Associates LP (0.78%), State Street Corp (0.74%), Northern Trust Corp (0.64%) and Bank of New York Mellon Corp (0.25%). View Institutional Ownership Trends for Abeona Therapeutics.
Who sold Abeona Therapeutics stock? Who is selling Abeona Therapeutics stock?
Who bought Abeona Therapeutics stock? Who is buying Abeona Therapeutics stock?
Abeona Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Northern Trust Corp, Vanguard Group Inc., Essex Investment Management Co. LLC, TIAA CREF Investment Management LLC, Bank of New York Mellon Corp, Teachers Advisors LLC and California State Teachers Retirement System. View Insider Buying and Selling for Abeona Therapeutics.
How do I buy Abeona Therapeutics stock?
Shares of Abeona Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Abeona Therapeutics' stock price today?
MarketBeat Community Rating for Abeona Therapeutics (NASDAQ ABEO)MarketBeat's community ratings are surveys of what our community members think about Abeona Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Abeona Therapeutics stock can currently be purchased for approximately $7.80.
Earnings History for Abeona Therapeutics (NASDAQ:ABEO)Earnings History by Quarter for Abeona Therapeutics (NASDAQ ABEO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/13/2017|| || || || || || || || |
|8/15/2017||Q2 2017||($0.14)||($0.21)||$0.21 million||$0.22 million||View||N/A|
|5/18/2017||Q1 2017||($0.15)||($0.13)||$0.28 million||$0.19 million||View||N/A|
|3/31/2017||12/31/2016||($0.14)||($0.19)||$0.19 million||$0.26 million||View||N/A|
|11/14/2016||Q316||($0.19)||($0.08)||$0.23 million||$0.18 million||View||N/A|
|8/16/2016||Q2||($0.14)||($0.20)||$0.27 million||$0.21 million||View||N/A|
Earnings Estimates for Abeona Therapeutics (NASDAQ:ABEO)
2017 EPS Consensus Estimate: ($0.47)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Abeona Therapeutics (NASDAQ:ABEO)
No dividend announcements for this company have been tracked by MarketBeat.com
Headline Trends for Abeona Therapeutics (NASDAQ:ABEO)
Latest Headlines for Abeona Therapeutics (NASDAQ:ABEO)
|Jefferies Group Comments on Abeona Therapeutics Inc.'s Q3 2017 Earnings (ABEO)|
www.americanbankingnews.com - August 18 at 7:20 AM
|Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017 - Nasdaq|
www.nasdaq.com - August 18 at 1:35 AM
|Leading Biotech Companies Receiving Orphan Drug Designation in 2017|
www.bizjournals.com - August 17 at 3:31 PM
|ABEONA THERAPEUTICS INC|
www.finanznachrichten.de - August 17 at 3:31 PM
|Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017|
feeds.benzinga.com - August 17 at 9:55 AM
|Abeona Therapeutics Inc. (ABEO) Cut to "Hold" at Zacks Investment Research|
www.americanbankingnews.com - August 16 at 9:34 PM
|BRIEF-Abeona Therapeutics expands gene therapy clinical trials in Sanfilippo Syndrome Type A|
www.reuters.com - August 16 at 8:24 PM
|Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome ... - GlobeNewswire (press release)|
globenewswire.com - August 16 at 3:21 PM
|Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A|
finance.yahoo.com - August 16 at 3:21 PM
|Maxim Group Analysts Give Abeona Therapeutics Inc. (ABEO) a $17.00 Price Target|
www.americanbankingnews.com - August 16 at 3:12 PM
|Abeona Therapeutics Inc. (ABEO) Releases Earnings Results, Misses Expectations By $0.07 EPS|
www.americanbankingnews.com - August 16 at 10:38 AM
|Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights - GlobeNewswire (press release)|
globenewswire.com - August 15 at 3:22 PM
|Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights|
finance.yahoo.com - August 15 at 3:22 PM
|Abeona Therapeutics reports 2Q loss|
finance.yahoo.com - August 15 at 3:22 PM
| Brokerages Anticipate Abeona Therapeutics Inc. (ABEO) Will Post Quarterly Sales of $230,000.00|
www.americanbankingnews.com - August 14 at 10:14 AM
| Analysts Anticipate Abeona Therapeutics Inc. (NASDAQ:ABEO) Will Post Earnings of -$0.12 Per Share|
www.americanbankingnews.com - August 12 at 2:12 AM
|Top Companies Receiving Orphan Drug Designation in 2017|
www.prnewswire.com - July 28 at 3:28 PM
|Abeona Therapeutics Inc. (NASDAQ:ABEO) Expected to Announce Quarterly Sales of $230,000.00|
www.americanbankingnews.com - July 26 at 10:37 AM
|Abeona Therapeutics (ABEO) Appoints Juan Ruiz as CMO - StreetInsider.com|
www.streetinsider.com - July 26 at 1:22 AM
|Abeona Therapeutics Inc. (NASDAQ:ABEO) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - July 25 at 3:07 PM
|Global Genes Announces RARE Champion of Hope Award Recipients to be Honored at 6th Annual RARE Tribute and Patient Advocacy Summit|
www.bizjournals.com - July 25 at 12:03 AM
| Brokerages Anticipate Abeona Therapeutics Inc (NASDAQ:ABEO) Will Post Earnings of -$0.12 Per Share|
www.americanbankingnews.com - July 24 at 10:18 PM
|STORY REMOVED: BC-US--Earns-Abeona Therapeutics|
marketbeat.com - July 21 at 4:46 PM
|Abeona Therapeutics reports 4Q loss|
finance.yahoo.com - July 21 at 4:29 PM
|HC Wainwright Analysts Give Abeona Therapeutics Inc. (NASDAQ:ABEO) a $20.00 Price Target|
www.americanbankingnews.com - July 20 at 12:58 AM
|Cantor Fitzgerald Reiterates "$21.00" Price Target for Abeona Therapeutics Inc. (ABEO)|
www.americanbankingnews.com - July 18 at 5:30 PM
|Abeona Therapeutics Receives Guidance from FDA to Commence ... - Nasdaq|
www.nasdaq.com - July 18 at 3:20 PM
|Abeona Therapeutics Receives Guidance from FDA to Commence Pivotal Phase 3 for EB-101 Gene Therapy for Patients with Epidermolysis Bullosa|
finance.yahoo.com - July 18 at 3:20 PM
|Abeona Therapeutics Inc. (ABEO) Receives Buy Rating from Maxim Group|
www.americanbankingnews.com - July 18 at 3:10 PM
|BUZZ-US STOCKS ON THE MOVE- Abercombie, Clubcorp, Inotek, PayPal - Nasdaq|
www.nasdaq.com - July 10 at 3:24 PM
|ETFs with exposure to Abeona Therapeutics, Inc. : July 10, 2017|
finance.yahoo.com - July 10 at 3:24 PM
|Abeona Therapeutics Inc. (ABEO) Raised to Buy at BidaskClub|
www.americanbankingnews.com - July 8 at 2:20 PM
|Ahead of this year's MLB All-Star Game, here are 4 home r...|
finance.yahoo.com - July 8 at 8:19 AM
|Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6% - Nasdaq|
www.nasdaq.com - July 6 at 4:40 PM
|Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 10.6%|
finance.yahoo.com - July 6 at 4:40 PM
|The 11 Biggest and Best Analyst Upgrades of June|
www.marketwatch.com - July 1 at 3:18 PM
|Abeona Therapeutics (ABEO) Announces FDA Orphan Drug Designation for ABO-201 - StreetInsider.com|
www.streetinsider.com - June 30 at 8:26 PM
|Abeona Therapeutics Inc. (ABEO) Expected to Post Quarterly Sales of $230,000.00|
www.americanbankingnews.com - June 30 at 12:25 PM
|Abeona Therapeutics Inc. (ABEO) Given Average Recommendation of "Buy" by Analysts|
www.americanbankingnews.com - June 30 at 8:37 AM
|Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy ... - GlobeNewswire (press release)|
globenewswire.com - June 29 at 3:19 PM
|Abeona Therapeutics Receives FDA Orphan Drug Designation for ABO-201 Juvenile Batten Disease Gene Therapy Program|
finance.yahoo.com - June 29 at 3:19 PM
|Abeona Therapeutics Inc. (ABEO) Expected to Post Earnings of -$0.12 Per Share|
www.americanbankingnews.com - June 28 at 6:28 PM
|ETFs with exposure to Abeona Therapeutics, Inc. : June 28, 2017|
finance.yahoo.com - June 28 at 3:36 PM
|Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector - Forbes|
www.forbes.com - June 27 at 3:20 PM
|Rare Diseases: Biotech's High Risk, Highest Reward Sub-Sector|
finance.yahoo.com - June 27 at 3:20 PM
|Brokers Set Expectations for Abeona Therapeutics Inc.'s Q3 2017 Earnings (ABEO)|
www.americanbankingnews.com - June 26 at 7:41 AM
|Abeona Therapeutics Inc. (ABEO) Expected to Earn Q2 2017 Earnings of ($0.12) Per Share|
www.americanbankingnews.com - June 23 at 8:33 AM
|Abeona Therapeutics Inc. (ABEO) Now Covered by Analysts at Jefferies Group LLC|
www.americanbankingnews.com - June 22 at 11:02 AM
|ETFs with exposure to Abeona Therapeutics, Inc. : June 16, 2017|
finance.yahoo.com - June 16 at 8:21 PM
|Abeona Therapeutics Inc (ABEO) Upgraded by Zacks Investment Research to "Hold"|
www.americanbankingnews.com - June 9 at 10:10 PM
Abeona Therapeutics (ABEO) Chart for Saturday, August, 19, 2017